Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis

CONCLUSION: Overall, results were consistent with those reported in the male population enrolled in the HAVEN 6 study, suggesting efficacy and a favorable safety profile for emicizumab in females with non-severe HA warranting prophylaxis.PMID:38193069 | PMC:PMC10772889 | DOI:10.1016/j.rpth.2023.102239

Source: Thrombosis and Haemostasis - January 9, 2024 Category: Hematology Authors: Cedric Hermans Giuliana Ventriglia Samya Obaji Benjamin M Beckermann Michaela Lehle Olivier Catalani Roseline d'Oiron Laurent Frenzel Source Type: research